Therapeutic Vaccine Prevents Pancreatic Cancer's Recurrence in 3-Year Trial
By Dennis Thompson HealthDay Reporter
MONDAY, April 8, 2024 -- A pancreatic cancer vaccine has continued to protect a small group of patients from their cancer coming back, three years after receiving the jab, a new study says.
Eight patients have not had their pancreatic cancer recur for three years after their immune systems responded to the vaccine, which is called autogene cevumeran, researchers reported Sunday at a meeting of the American Association for Cancer Research in San Diego.
Pancreatic cancer is a highly fatal disease, researchers noted. Even after successful surgery, only about 12% of patients are alive five years after diagnosis, according to the American Association of Clinical Oncology.
“Chemotherapy, radiation, targeted therapy, and current immunotherapies are also largely ineffective in pancreatic cancer, so new therapies are urgently needed for patients who face this deadly disease,” researcher Dr. Vinod Balachandran, a surgical oncologist with Memorial Sloan Kettering Cancer Center in New York City, said in a news release.
The mRNA-based vaccine teaches the immune system to identify and attack cancer cells, using 20 unique proteins exclusively present in a patient’s tumor. The vaccine is special-made for each patient, based on the specific mutations found in their cancer, Balachandran said.
The research team compared eight patients who responded to the vaccine with eight patients who didn’t. All had undergone surgery to remove their cancer.
Those who didn’t respond to the vaccine had an average recurrence-free survival rate of 13 months, results show.
But those whose immune systems did learn from the vaccine have remained cancer-free for three years, researchers said.
Researchers also found expanded levels of cancer-fighting immune cells throughout the bodies of those eight patients, results show.
The data shows that the vaccine can create cancer-fighting immune cells “with significant longevity, substantial magnitude, and durable function,” Balachandran said.
An ongoing clinical trial is testing how the autogene cevumeran vaccine works in combination with chemotherapy and the immunotherapy drug atezolizumab, compared against standard chemotherapy, Balachandran said.
The clinical trial was funded in part by Genentech and BioNTech, the developers of autogene cevumeran.
Results presented at a medical meeting should be considered preliminary until published in a peer-reviewed journal.
Sources
- American Association for Cancer Research, news release, April 7, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Most Cancer Treatments Near End of Life Are Useless: Study
FRIDAY, May 17, 2024 -- Cutting-edge cancer treatments are essentially useless for patients barely clinging to life, a new study shows. Chemotherapies, immunotherapies, targeted...
Why C-Section Babies Need 2 Doses of Measles Vaccine
TUESDAY, May 14, 2024 -- Babies born by C-section are unlikely to receive protection from a single dose of measles vaccine, a new study finds. A single measles jab is up to 2.6...
There's a New Set of COVID Variants Called FLiRT: What You Need to Know
WEDNESDAY, May 8, 2024 -- The virus behind COVID has mutated again, this time producing variants nicknamed FLiRT, the U.S. Centers for Disease Control and Prevention (CDC) has...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
